Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Greater US FDA And Manufacturer Transparency Recommended As Key to Supply Chain Resilience

Executive Summary

Manufacturers could risk losing FDA product approvals if they fail to publicize sourcing and quality information, under new proposals. National Academies expert panel says supply chain transparency – not a pandemic-induced rush to onshoring requirements  –  provides the framework to mitigate against and respond to drug shortages.

You may also be interested in...



Global Supply Chain Scrutiny And Investment In Domestic Alternatives For US Drug Shortages

Pharmaceutical supply chains may grow less efficient and less risk prone as US government gets more involved to ensure availability of pandemic and essential medicines. But what about pediatric oncology medicines and other treatments that save lives even though they may not be considered essential?

US FDA Needs ‘More Clout’ To Get Supply Chain Information, Califf Says

‘It’s driving me crazy that supply chains are a trade secret,’ FDA commissioner states. Agency also needs more clout to handle accelerated approvals, he tells gathering of industry executives and government policy makers.

US FDA Needs ‘More Clout’ To Get Supply Chain Information, Califf Says

‘It’s driving me crazy that supply chains are a trade secret,’ FDA commissioner states. Agency also needs more clout to handle accelerated approvals, he tells gathering of industry executives and government policy makers.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS145801

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel